Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030 and $1.5 billion principal amount of 3.150% senior notes due 2050. Proceeds of the offering will be used to redeem certain outstanding senior notes, to fund repurchases of common stock pursuant to its stock repurchase program and for working capital and other general corporate purposes.

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen is focused on discovering, developing and delivering worldwide innovative therapies in emerging growth areas of immunology; neurocognitive disorders; acute neurology and pain.

The Davis Polk capital markets team included partner Michael Kaplan and associates Arisa Akashi and Moses Farzan Nekou. Partner David R. Bauer, counsel Bonnie Chen and associate Chelsea Renter provided intellectual property advice. The tax team included partner Po Sit and associate Eitan Ulmer. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post